ImmunoGen (IMGN) Shares are Up 3.26%

ImmunoGen (IMGN) has been under a strong bear grip, hence the stock is down -14.71% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 2.63% in the past 1 week. The stock has risen by 3.26% in the past week indicating that the buyers are active at lower levels, but the stock is down -8.95% in the past 4 weeks.

ImmunoGen (NASDAQ:IMGN): The stock was completely flat for the day, closing at $2.85 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $2.85, the stock touched an intraday high of $2.89 and a low of $2.81. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $2.85. The total trading volume on Friday was 953,545.


The stock has recorded a 20-day Moving Average of 5.82% and the 50-Day Moving Average is 32.76%. ImmunoGen, Inc. has dropped 69.29% during the last 3-month period . Year-to-Date the stock performance stands at -79%.

ImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Companys clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells. The Company has three clinical-stage anticancer compounds: mirvetuximab soravtansine (IMGN853), coltuximab ravtansine, IMGN529, and IMGN779. The Companys partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company (Lilly), Novartis Institutes for BioMedical Research, Inc. (Novartis), the Roche Group, Sanofi and Takeda. The Companys collaborative partner compounds include Kadcyla, Indatuximab ravtansine, Isatuximab, Anetumumab ravtansine, AMG 595, AMG 172, SAR566658, SAR408701, LOP628 and PCA062. All of the Companys compounds are ADCs with the exception of isatuximab, which is a therapeutic antibody.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.